(Q40659435)

22 September 2017

title

Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene (English)

1 reference

22 September 2017

1 reference

Frisbie DD

1 reference

22 September 2017

Ghivizzani SC

1 reference

22 September 2017

Robbins PD

1 reference

22 September 2017

Evans CH

1 reference

22 September 2017

McIlwraith CW

1 reference

22 September 2017

publication date

1 January 2002

1 reference

22 September 2017

1 reference

22 September 2017

1 reference

22 September 2017

1 reference

22 September 2017

page(s)

12-20

1 reference

Gene therapy for rheumatic diseases

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301608

Potential treatment of osteoarthritis by gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301608

The role of gene therapy. Fact or fiction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301608

Inhibition of interleukin-1-induced effects in synoviocytes transduced with the human IL-1 receptor antagonist cDNA using an adenoviral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301608

Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301608

In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301608

Adenoviral-mediated gene transfer to rabbit synovium in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301608

Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301608

Inhibition of interleukin-1-induced synovitis and articular cartilage proteoglycan loss in the rabbit knee by recombinant human interleukin-1 receptor antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301608

Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301608

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301608

The synovial lining cell: biology and pathobiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301608

Role of synovial membrane inflammation in cartilage matrix breakdown in the Pond-Nuki dog model of osteoarthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301608

The assessment of chondrocyte proteoglycan metabolism using molecular sieve column chromatography as compared to three commonly utilized techniques

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301608

Gene therapy of arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301608

7 January 2021

Effects of equine recombinant interleukin-1alpha and interleukin-1beta on proteoglycan metabolism and prostaglandin E2 synthesis in equine articular cartilage explants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301608

7 January 2021

Biologic effects of an interleukin-1 receptor antagonist protein on interleukin-1–stimulated cartilage erosion and chondrocyte responsiveness

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301608

7 January 2021

Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301608

7 January 2021

Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301608

7 January 2021

Meaningful improvement criteria sets in a rheumatoid arthritis clinical trial. MIRA Trial Group. Minocycline in Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301608

7 January 2021

Effects of triamcinolone acetonide on anin vivoequine osteochondral fragment exercise model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301608

7 January 2021

Identifiers

DOI

10.1038/SJ.GT.3301608

1 reference

Dimensions Publication ID

22 September 2017

1041387729

0 references

1 reference